Skip to main content
. 2020 Feb 14;19(3):e13113. doi: 10.1111/acel.13113

Figure 1.

Figure 1

TRPV1 decreases APP processing in APP23/PS45 mice. (a) The protein level of TRPV1 in the brains of WT and APP23/PS45 mice at the age of 4 months. t = 40.605, p < .001 by unpaired Student's t test. n = 6 in each group. (b–h) The relative protein levels of TRPV1 (b and c), APP (b and d), c99 (b and e), c89 (b and f), BACE1 (b and g), and PS1 (b and h) are normalized by WT (n = 4–9 in each group). One‐way ANOVA: F (3,17) = 28.993, p < .001 for TRPV1; F (3,29) = 13.818, p < .001 for APP; F (3,13) = 27.499, p < .001 for c99; F (3,13) =7.871, p = .004 for c89; F (3,17) =14.975, p < .001 for BACE1; and F (3,25) = 4.488, p = .012 for PS1. (i and j) The number of neuritic plaques detected by immunohistochemistry in the hippocampus of APP23/PS45 mice (n = 14–42 slices from 3–9 mice in each group). One‐way ANOVA: F (3,122) = 15.092, p < .001. Data are expressed as mean ± SEM, *p < .05, **p < .01, ***p < .001